Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MiTest Health
- Ownership
- Private
- Development stage
- Other
01
Overview
The MiTest Health predictive tool for Crohn’s disease uses serologic and genetic markers (including NOD2) and clinical variables to stratify individual patient risk for complications, creating visual reports to assist shared clinical decisions. The tool has been validated in a well-characterized adult CD cohort and is being scaled for wider clinical implementation in partnership with Takeda[1][2][3].
- Therapeutic areas
- GastroenterologyOther
- Modalities
- DeviceDigital health platformComputerized risk assessment tool
- Industry
- Digital Health Medical Devices
02
Partnerships
Takeda Pharmaceuticals U.S.A.
Beyond the preview
Go deeper on MiTest Health.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MiTest Health.